SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-16-759511
Filing Date
2016-11-04
Accepted
2016-11-04 07:11:02
Documents
3
Period of Report
2016-11-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d196831d8k.htm 8-K 39160
2 EX-99.1 d196831dex991.htm EX-99.1 17760
3 GRAPHIC g196831aimmune.jpg GRAPHIC 17597
  Complete submission text file 0001193125-16-759511.txt   82752
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37519 | Film No.: 161973606
SIC: 2834 Pharmaceutical Preparations